How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,738 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

41. Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. (PubMed)

Patients with Moderate to Severe Psoriasis Associate with Higher Risk of Depression and Anxiety Symptoms: Results of a Multivariate Study of 300 Spanish Individuals with Psoriasis. Psoriasis is a chronic skin disease associated with considerable physical and psychological co-morbidities. Stress and emotional disturbances have been implicated in both triggering the onset and exacerbation of psoriasis. In order to determine the level of perceived stress and mood alterations in patients (...) with psoriasis and their association with disease severity, 300 individuals completed diverse validated questionnaires assessing stress and psychological mood. Evaluation of perception of disease was also measured. A significant association between psoriasis severity and mood, emotional disturbances and an impact on assessments of the quality of life were observed. Particularly, Montgomery-Asberg Depression Rating Scale, Hamilton Rating Scale and Hospital Anxiety and Depression Scale for Depression detected

Full Text available with Trip Pro

2019 Acta Dermato-Venereologica

42. Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. (PubMed)

Recommendations for the definition, evaluation, and treatment of nail psoriasis in adult patients with no or mild skin psoriasis: a dermatologist and nail expert group consensus. Nail involvement in psoriasis is common, and the severity of it does not always parallel the intensity of cutaneous disease. We created a consensus group, of which the aim was to provide practical recommendations for the treatment of nail psoriasis in patients without skin psoriasis, or with mild skin lesions (...) with no indication for a systemic treatment. This collaborative process was conducted by an international panel of dermatologists with special expertise in nail disorders, using a formal consensus methodology. During this process, the panel strived to establish an agreement regarding the definition of nail psoriasis, the severity of nail psoriasis, and treatment response. Treatment recommendations are provided regarding nail psoriasis severity and matrix or bed involvement. "Few-nail" disease was considered

2019 Journal of American Academy of Dermatology

43. Institute for Clinical and Economic Review (ICER) Psoriasis Update 2018: What it means for dermatologists treating moderate-to-severe plaque psoriasis. (PubMed)

Institute for Clinical and Economic Review (ICER) Psoriasis Update 2018: What it means for dermatologists treating moderate-to-severe plaque psoriasis. This paper aims to summarize the key findings of the updated report issued in August 2018 by the Institute of Clinical and Economic Review (ICER) regarding the clinical efficacy and budget impact of various immunomodulators.This paper specifically focuses on the inclusion of two new biologics, guselkumab and certolizumab in the context (...) for more consensus guidelines in the use of biologics in the treatment of psoriasis, and perhaps consideration of costs within these guidelines.

2019 Journal of Dermatological Treatment

44. Long-term maintenance of secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. (PubMed)

Long-term maintenance of secukinumab in psoriasis: association with patient profile and initial psoriasis clearance. There is limited data regarding the long-term persistence of biological therapy in patients with psoriasis. In particular, reasons of secukinumab discontinuation have not been thoroughly investigated.To better ascertain the real life maintenance of secukinumab in psoriasis, we conducted a retrospective study to evaluate the incidence, causes and factors of secukinumab (...) discontinuation in patients with psoriasis.All patients treated with secukinumab for psoriasis in the dermatology department of Toulouse, France, between September 2011 and June 2017, were included.Among 91 patients included; 22 (24, 2%) patients discontinued secukinumab. In 14 (15%) patients, the discontinuation was due to loss of efficacy. Two patients stopped treatment because of a desire for pregnancy, five patients due to the occurrence of adverse events. A longer disease duration (p = 0,01

2019 Clinical & Experimental Dermatology

45. Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council. (PubMed)

Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council. Psoriasis in children can be a challenging diagnosis: the clinical presentation is often more subtle, may occur in covered sites and can be an unexpected diagnosis as psoriasis if often thought to occur at older ages. Poor recognition and delayed diagnosis of psoriasis in children can lead to inadequate treatment and lack of monitoring

2019 British Journal of Dermatology

46. US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. (PubMed)

US real-world effectiveness of secukinumab for the treatment of psoriasis: 6-month analysis from the Corrona Psoriasis Registry. To examine the real-world effectiveness of secukinumab with regard to clinical and patient-reported outcomes (PROs) from enrollment to a 6-month follow-up visit in patients with psoriasis in the Corrona Psoriasis Registry.Eligible patients aged ≥ 18 years who initiated secukinumab at enrollment in the Corrona Psoriasis Registry and had a 6-month follow-up visit

Full Text available with Trip Pro

2019 Journal of Dermatological Treatment

47. Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. (PubMed)

Impact of psoriasis severity on patient-reported clinical symptoms, health-related quality of life and work productivity among US patients: real-world data from the Corrona Psoriasis Registry. This analysis examined the association between psoriasis severity, assessed by body surface area (BSA) and the Investigator's Global Assessment (IGA; previously used only in clinical trials), and patient-reported outcomes (PROs) in a real-world setting.Cross-sectional analysis within the Corrona Psoriasis (...) Registry, an independent, prospective registry.70 dermatology practices in the USA.1529 adult patients with psoriasis being treated with biological or non-biological systemic psoriasis treatment by 31 May 2016.Psoriasis severity was assessed by percentage of affected BSA (mild (0%-5%), moderate (>5%-10%), severe (>10%-15%), very severe (>15%)) and IGA scores (clear/almost clear (0-1), mild (2), moderate (3), severe (4)). PROs (pain, itch, fatigue; Dermatology Life Quality Index [DLQI]; EuroQoL Visual

Full Text available with Trip Pro

2019 BMJ open

48. Psoriasis and liver fibrosis: an investigation using transient elastography in Tunisian patients with psoriasis. (PubMed)

Psoriasis and liver fibrosis: an investigation using transient elastography in Tunisian patients with psoriasis. We investigated the prevalence of liver fibrosis in psoriatic patients and evaluated the factors associated with liver fibrosis in this population. We enrolled 112 patients with psoriasis aged of 18 years or older. We excluded pregnant women, patients with known liver diseases, heavy alcohol drinkers and regular users of hepatotoxic medications other than methotrexate. Psoriasis (...) was defined as severe in following conditions: PASI≥10, or generalized pustular, erythrodermic or arthropathic psoriasis, or requirement of a systemic medication. Anthropometric measurements were performed. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

49. The top ten research priorities for psoriasis in the UK; results of a James Lind Alliance psoriasis priority setting partnership. (PubMed)

The top ten research priorities for psoriasis in the UK; results of a James Lind Alliance psoriasis priority setting partnership. Psoriasis is an immune-mediated inflammatory skin disease, with a prevalence of 0·09% to 11·4%, which affects approximately two million people in the U.K.1,2 It has a significant psychological and social impact on affected individuals, is associated with co-morbidities such as depression, cardiovascular disease and inflammatory arthritis, and confers a substantial (...) economic burden on the National Health Service.1-3 Access to appropriate care that addresses the high health-care burden and complex interlinked physical, psychological and social needs of those who have psoriasis is often poor. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

50. Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. (PubMed)

Development of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis: qualitative and quantitative analyses. Background: Psoriasis is a chronic inflammatory skin disease. Objective: To establish content validity and assess psychometric properties of the Psoriasis Symptoms Scale (PSS) in patients with moderate-to-severe psoriasis (Ps). Methods: The PSS is an eight-item patient-completed questionnaire assessing symptoms (itch, pain, stinging, burning), signs (redness

2019 Journal of Dermatological Treatment

51. Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. (PubMed)

Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. The Psoriasis Symptom Inventory (PSI) is a patient-reported outcome measure designed to assess psoriasis signs and symptoms.The aim was to assess the usefulness of the PSI in enhancing patient care in the clinical setting.Eight dermatology clinics in six countries enrolled adults representing the full spectrum of psoriasis severity who regularly received (...) care at the clinic. Patients were administered the eight-item PSI (score range 0-32; higher scores indicate greater severity) while waiting for the physician; the physician conducted a static physician global assessment (sPGA) and estimated psoriasis-affected body surface area (BSA) at the same visit. Physicians completed a brief questionnaire after each patient visit, and were interviewed about the PSI after all patients were seen.The clinics enrolled 278 patients; mean [standard deviation (SD

2019 American journal of clinical dermatology

52. Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes. (PubMed)

Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes. Treatment goals defined by the absolute Psoriasis Area and Severity Index (PASI) scores offer certain advantages in the clinical setting. In order to investigate potential treatment targets, this study evaluated absolute PASI outcomes relative (...) to other measures of response using data from two randomized clinical trials of patients with moderate-to-severe psoriasis treated with ixekizumab, etanercept, or placebo (n=2,567). Response was assessed throughout 12 weeks as the proportion of patients achieving absolute PASI band cut-offs who also reached established response criteria. Most PASI band ≤2 responders also achieved PASI 90 (70.1-100%), static Physician's Global Assessment (0,1) (91.3-96.1%), Dermatology Life Quality Index (0,1) (63.0

2019 Acta Dermato-Venereologica

53. The association of scalp psoriasis with overall psoriasis severity and koebnerization in children: cross-sectional findings from the Dutch ChildCAPTURE registry. (PubMed)

The association of scalp psoriasis with overall psoriasis severity and koebnerization in children: cross-sectional findings from the Dutch ChildCAPTURE registry. Scalp psoriasis can be a physical and psychological burden for patients irrespective of overall psoriasis severity and is difficult to treat. Studies on scalp psoriasis in children and potential associations with clinical characteristics are sparse. In children, the scalp is commonly reported as the initial site of presentation (...) and scalp psoriasis tends to develop more frequently in girls than in boys. One multicenter study reported scalp psoriasis more frequently in severe psoriasis versus moderate psoriasis but the finding did not reach statistical significance. This article is protected by copyright. All rights reserved.This article is protected by copyright. All rights reserved.

2019 British Journal of Dermatology

54. Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments. (PubMed)

Changes in serum TNF-like weak inducer of apoptosis (TWEAK) levels and Psoriasis Area Severity Index (PASI) scores in plaque psoriasis patients treated with conventional versus anti-TNF treatments. Psoriasis is a chronic dermatologic disease affecting 2% of the general population. Tumour necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) is a newly defined member of the TNF family. Increased serum levels of TWEAK were reported in inflammatory diseases. The relationship between serum (...) TWEAK levels and severity of psoriasis has not yet been proven. Our aim was to clarify the change in serum TWEAK levels in response to conventional and anti-TNF treatments.Blood samples were collected from 103 moderate or severe chronic plaque psoriasis patients with or without arthritis who were referred to the Department of Dermatology, Istanbul University Cerrahpasa Medical Faculty between the years 2016 and 2018. Psoriasis Area and Severity Index (PASI) scores were calculated, and serum TWEAK

2019 International Journal of Dermatology

55. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. (PubMed)

Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management and treatment of psoriasis with phototherapy. Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approximately 3.2% of the world's population. In this section of the guidelines of care for psoriasis, we will focus the discussion on ultraviolet (UV) light-based therapies, which include narrowband and broadband UVB, UVA in conjunction (...) with photosensitizing agents, targeted UVB treatments such as with an excimer laser, and several other modalities and variations of these core phototherapies, including newer applications of pulsed dye lasers, intense pulse light, and light-emitting electrodes. We will provide an in-depth, evidence-based discussion of efficacy and safety for each treatment modality and provide recommendations and guidance for the use of these therapies alone or in conjunction with other topical and/or systemic psoriasis

2019 Journal of American Academy of Dermatology

56. Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. (PubMed)

Re-Categorization of Psoriasis Severity: Delphi Consensus from the International Psoriasis Council. Psoriasis severity categories have been important tools for clinicians to use in treatment decisions as well as to determine eligibility criteria for clinical studies. However, due to the heterogeneity of severity classifications and their lack of consideration for the impact of psoriasis involvement of special areas or past treatment history, patients may be mis-categorized, which can lead (...) to under-treatment of psoriasis.To develop a consensus statement on the classification of psoriasis severity.A modified Delphi approach was developed by the International Psoriasis Council to define psoriasis severity.After completion of the exercise, seven severity definitions were preferentially ranked. This most preferred statement rejects the mild, moderate and severe categories in favor of a dichotomous definition: Psoriasis patients should be classified as either candidates for topical therapy

2019 Journal of American Academy of Dermatology

57. Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. (PubMed)

Secukinumab demonstrates improvements in absolute and relative psoriasis area severity indices in moderate-to-severe plaque psoriasis: results from a European, multicentric, retrospective, real-world study. Objective: This European, multicentric, retrospective study aimed to collect data on secukinumab effectiveness in a real-world setting. Research design and methods: All psoriatic patients starting secukinumab between January 2016 and February 2017 in 11 European centers were followed until (...) February 2018 and retrospectively evaluated. Main outcome measures: Secukinumab effectiveness was assessed by relative improvement from baseline of the Psoriasis Area Severity Index (PASI) and absolute PASI score modifications throughout 52 weeks of therapy. Additionally measures assessing effectiveness were used, including improvements of body surface area (BSA) and Dermatology Life Quality Index (DLQI). Results: Out of the 330 patients with potentially 52-week treatment duration, naïve to biologics

2019 Journal of Dermatological Treatment

58. Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. (PubMed)

Characterization of insufficient responders to anti-tumor necrosis factor therapies in patients with moderate to severe psoriasis: real-world data from the US Corrona Psoriasis Registry. Objective: Biologic therapies have dramatically changed the management of moderate to severe psoriasis; however, few US real-world studies characterize the unmet needs of patients who do not respond to biologic therapies. This study examined the characteristics at enrollment of patients with moderate to severe (...) psoriasis who had insufficient responses to anti-tumor necrosis factor therapies (anti-TNFs). Methods: Patients enrolled in the Corrona Psoriasis Registry from April 2015 to June 2018 who initiated an anti-TNF at enrollment were stratified on the basis of body surface area (BSA) improvement to <3% or a 75% improvement from enrollment to the 6-month follow-up visit (response versus insufficient response). Patient demographics and disease characteristics were described at enrollment, and changes

2019 Journal of Dermatological Treatment

59. Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). (PubMed)

Psoriasis treat to target: defining outcomes in psoriasis using data from a real-world, population-based cohort study (the British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR). The 'treat to target' paradigm improves outcomes and reduces costs in chronic disease management but is not yet established in psoriasis.To identify treatment targets in psoriasis using two common measures of disease activity: Psoriasis Area and Severity Index (PASI) and Physician's (...) Global Assessment (PGA).Data from a multicentre longitudinal U.K. cohort of patients with psoriasis receiving systemic or biologic therapies (British Association of Dermatologists Biologics and Immunomodulators Register, BADBIR) were used to identify absolute PASI thresholds for 90% (PASI 90) and 75% (PASI 75) improvements in baseline disease activity, using receiver operating characteristic curves. The relationship between PGA (clear, almost clear, mild, moderate, moderate-severe, severe) and PASI

2019 British Journal of Dermatology

60. Quality of Life in Psoriasis Vulgaris: Use of the ItchyQoL Question-naire in a Secukinumab Phase III Trial in Patients with Psoriasis Vulgaris. (PubMed)

Quality of Life in Psoriasis Vulgaris: Use of the ItchyQoL Question-naire in a Secukinumab Phase III Trial in Patients with Psoriasis Vulgaris. Chronic pruritus is a bothersome symptom in psoriasis vulgaris and can profoundly reduce quality of life (QoL). In this exploratory analysis of the PSORITUS study, the impact of pruritus on QoL in 130 subjects with moderate-to-severe psoriasis was assessed using the ItchyQoL questionnaire. The majority of patients (n = 127) had to scratch their itchy (...) questionnaire as a validated tool responsive to treatment for detailed insights into chronic pruritus in patients with psoriasis.

2019 Acta Dermato-Venereologica

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>